Logo

DiscoveryBioMed to Conduct Bioassay Testing for Lifeline

Feb 19, 2009

NEW YORK (GenomeWeb News) – DiscoveryBioMed today said that it has inked a service contract with Lifeline Cell Technology to conduct primary human cell bioassay testing for the subsidiary of International Stem Cell Corp.

The contract partners DBM's expertise in assay development with Lifeline's expertise in producing optimized human adult and stem cell products, said Lifeline CEO Jeffrey Janus.

Birmingham, Ala.-based DBM also said that the partners are developing a mutual Small Business Innovation Research grant proposal based on using multiple human cell cultures derived from different tissues as an in vitro platform for testing pollutant, candidate therapeutics and existing drugs for toxicity against cells.

Financial and other terms of the contract were not disclosed.

Breaking News
The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.